Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building Trust, Technology Competence Can Boost Partnering Prospects For Indian, U.S. Companies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ( 'Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For 'Niche Busters' And Stem Cells,' PharmAsia News, May 23, 2011 ). In the second story, PharmAsia News' India bureau spoke with Biogen Idec SVP Gunther Winkler, who discussed the big biotech's strategy in India and important policy decisions facing the Indian government ( 'Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance,' PharmAsia News, June 13, 20110.

You may also be interested in...



Is India Falling Behind Its Neighbors In Attracting Clinical Research?

During the USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.

Is India Falling Behind Its Neighbors In Attracting Clinical Research?

During the annual USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.

Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance

In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ('Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells,' PharmAsia News, May 23, 2011). In this installment, we talk with Biogen Idec SVP Gunther Winkler, who discusses the big biotech's strategy in India and important policy decisions facing the Indian government.

Related Content

UsernamePublicRestriction

Register

SC078219

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel